Shasta View Care Center: Incomplete Consent Forms - CA
Shasta View Care Center failed to properly inform the resident about Abilify treatment, federal inspectors found during an August complaint investigation. The missing information violated the resident's right to understand their medical care.
Resident 1 was admitted to the facility in August 2024 with diagnoses of bipolar disorder and borderline personality disorder. The resident made their own medical decisions.
The day after admission, a physician ordered 30 milligrams daily of Aripiprazole, the generic name for Abilify. The antipsychotic medication alters brain function and treats extreme mood swings associated with bipolar disorder. The doctor's order noted that "verified informed consent had been obtained."
But the consent form was incomplete.
During interviews with inspectors on August 20, 2025, a licensed nurse reviewed the resident's consent document dated August 24, 2025. The form was titled "Consent and Disclosure of Risks and Benefits Regarding The Use of Anti-Psychotic Drugs."
"The consent was not correct," the nurse told inspectors. "The consent doesn't have the dose or why the medication was ordered."
The form failed to specify that the resident would receive 30 milligrams of Abilify daily. It also omitted the diagnosis that justified the prescription.
Two days later, the facility administrator acknowledged the problems during a follow-up interview. The administrator confirmed the Abilify consent was incomplete and missing required information.
Federal regulations require nursing homes to fully inform residents about their health status and treatments. The facility's own policy reinforced this standard, stating that residents would be "fully informed prior to initiating or increasing a psychotropic medication."
Psychotropic drugs carry significant risks and side effects. They can cause drowsiness, weight gain, diabetes, and involuntary muscle movements. Some effects are irreversible.
The incomplete consent form meant Resident 1 couldn't make a fully informed decision about treatment. Without knowing the specific dosage or medical reason for the prescription, the resident lacked critical information about their care.
Inspectors classified the violation as causing minimal harm but noted it could negatively affect the resident's psychosocial well-being. The deficiency affected few residents at the 99-bed facility.
The consent form remained incomplete for nearly a year. The original physician's order was dated August 23, 2024, but the flawed consent document wasn't identified until the August 2025 inspection.
Abilify is among the most commonly prescribed antipsychotic medications in nursing homes. The drug generated over $7 billion in annual sales before losing patent protection. Generic versions now cost significantly less but carry the same risks and requirements for informed consent.
Borderline personality disorder, one of Resident 1's diagnoses, involves long-term patterns of emotional instability and impulsive behaviors. Combined with bipolar disorder, the conditions can severely impact daily functioning and relationships.
The facility serves Red Bluff, a city of about 14,000 people in Northern California's Sacramento Valley. Shasta View Care Center operates as a skilled nursing facility providing both short-term rehabilitation and long-term care.
Federal inspectors noted that psychotropic medications require special attention because they affect brain chemistry and behavior. Facilities must document not only that consent was obtained, but that residents understand what they're agreeing to receive.
The missing dosage information was particularly significant. Abilify doses can range from 2 milligrams to 30 milligrams daily depending on the condition being treated and the patient's response. Higher doses increase the risk of side effects.
Without the diagnosis listed on the consent form, Resident 1 couldn't evaluate whether the potential benefits outweighed the risks for their specific condition. Bipolar disorder responds differently to antipsychotic treatment than other psychiatric conditions.
The violation occurred despite the facility's written policy requiring full disclosure before starting psychotropic medications. The gap between policy and practice left Resident 1 without essential information about their treatment for months.
Inspectors found the deficiency during a complaint investigation, suggesting someone reported concerns about the facility's consent practices. The specific nature of the complaint wasn't detailed in the public report.
The resident continues to receive Abilify while the facility works to correct its consent procedures.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Shasta View Care Center from 2025-08-22 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: June 20, 2026 · Our methodology
SHASTA VIEW CARE CENTER in RED BLUFF, CA was cited for violations during a health inspection on August 22, 2025.
Shasta View Care Center failed to properly inform the resident about Abilify treatment, federal inspectors found during an August complaint investigation.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.